

# Seelos Therapeutics

02:53 08 Mar 2019

## Seelos Therapeutics stock doubles on license of potential Parkinson's candidate created at UCLA

Seelos Therapeutics Inc (NASDAQ:SEEL) stock shot up Thursday after the biotech said it has exclusively in-licensed the rights to a potential disease modifying Parkinson's disease therapy created by researchers at the University of California, Los Angeles (UCLA).

Parkinson's disease is a progressive nervous system disorder that affects movement, and symptoms include tremors and changes in speech and gait.

Seelos Therapeutics stock nearly doubled to \$3.30 in morning trade.

### READ: Zynerba Pharmaceuticals launches Phase 2 trial of Zygel in autism spectrum disorder

The New York-based biotech has exclusively in-licensed the rights to a family of peptide inhibitors that target the aggregation of alpha-synuclein (?-synuclein).

The function of ?-synuclein proteins in the healthy brain is unknown, but Parkinson's researchers are interested in it because it is a major constituent of Lewy bodies, protein clumps that are the pathological hallmark of the neurological disorder.

The company has designed the new program as SLS-007, with an initial focus on Parkinson's disease.

Pre-clinical data provides supportive evidence to slow progression, an early sign of disease-modifying potential in Parkinson's disease.

Seelos will evaluate the potential for in-vivo delivery of SLS-007 in a Parkinson's disease transgenic mice model.

"Accumulation and aggregation of ?-synuclein is a pathological hallmark of Parkinson's disease," Seelos Therapeutics CEO Raj Mehra said in a statement. "Though its role is not completely understood, it appears pivotal in the pathogenesis of Parkinson's and other ?-synucleinopathies such as dementia with Lewy bodies and multiple system atrophy. Reducing the levels of pathological forms of ?-synuclein may alter the course of Parkinson's."

Tim Whitaker, who is the head of R&D at Seelos, said that the current available treatments for Parkinson's including Dopamine promoter Levodopa and deep brain stimulation, "long-term outcomes for patients remain poor."

"With no disease-modifying treatments, and long-term use of established dopaminergic therapies resulting in both adverse events and side effects, significant need remains to develop not only a better means of restoring striatal dopamine but a safe and effective treatment that slows progression of the disease in patients with Parkinson's," said Whitaker.

**Price:** 1.01

**Market Cap:** \$45.4 m

### 1 Year Share Price Graph



July 2019      January 2020      July 2020

### Share Information

**Code:** SEEL

**Listing:** NASDAQ

<b>52 week</b>	<b>High</b>	<b>Low</b>
	2.25	0.42

**Sector:** Pharma & Biotech

**Website:** seelostherapeutics.com

### Company Synopsis:

*Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare disorders. The Company's robust portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases.*

action@proactiveinvestors.com.au

Under the terms of the license, Seelos paid The UC Regents and UCLA \$100,000 upfront and will pay royalties on net sales.

Contact Uttara Choudhury at [uttara@proactiveinvestors.com](mailto:uttara@proactiveinvestors.com)

Follow her on Twitter: **@UttaraProactive**

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).